Advances in Glucagon

Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises the concentration of glucose and fatty acids in the bloodstream and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene.

In the present book, ten typical literatures about glucagon published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on glucagon. We hope this book can demonstrate advances in glucagon as well as give references to the researchers, students and other related people.

Sample Chapter(s)
preface (95 KB)
Components of the Book:
  • Chapter 1
    Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart
  • Chapter 2
    Glucagon‑like peptide‑1 and glucagon‑like peptide‑2 regulation during human liver regeneration
  • Chapter 3
    Secretion of glucagon, GLP‑1 and GIP may be affected by circadian rhythm in healthy males
  • Chapter 4
    GLP‑1 metabolite GLP‑1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
  • Chapter 5
    Eosinophil‑related diseases during treatment with glucagon‑like peptide one receptor (GLP‑1 RA): a case report and review of the literature
  • Chapter 6
    Comparing major and mild cognitive impairment risks in older type‑2 diabetic patients: a Danish register‑based study on dipeptidyl peptidase‑4 inhibitors vs. glucagon‑like peptide‑1 analogues
  • Chapter 7
    Feasibility study of Glucagon‑like peptide‑1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL‑AF) protocol
  • Chapter 8
    Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared with placebo and open‑label semaglutide in people with type 2 diabetes: a randomised clinical trial
  • Chapter 9
    Analysis and dynamical structure of glucose insulin glucagon system with Mittage‑Leffler kernel for type I diabetes mellitus
  • Chapter 10
    Combining glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) and sodium‑glucose cotransporter‑2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Readership: Students, academics, teachers and other people attending or interested in Glucagon.
Ramón Aranda-Domene
Department of Cardiovascular Surgery, Hospital CSV Arrixaca, El Palmar,30120 Murcia, Spain

Markus Ammann
Department of Surgery, State Hospital Wiener Neustadt, Wiener Neustadt, Austria

Nikhil R. Gandasi
Metabolic Physiology Unit, Department of Physiology,Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden

and more...
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top